| Symbol | HCM |
|---|---|
| Name | HUTCHMED (CHINA) LTD |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, None None |
| Telephone | 852-2121-3888 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001648257 |
| Description | None |
[Press Release] HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO GI 2026
Read moreHUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
Read more[Press Release] HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
Read moreHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
Read moreNew Form S-8 - HUTCHMED <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001104659-26-071540 <b>Size:</b> 445 KB
Read more[Press Release] HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Read moreHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Read more[Press Release] HUTCHMED Announces NMPA Approval for ELUNATE® plus TYVYT® for Locally Advanced or Metastatic Renal Cell Carcinoma
Read moreDirector Cheng Chig Fung 🟢 acquired 56.5K shares (2 derivative) of HUTCHMED (China) Ltd (HCM) Transaction Date: May 20, 2026 | Filing ID: 064789
Read moreNixon Charles George Rupert 🟢 acquired 15.1K shares (2 derivative) of HUTCHMED (China) Ltd (HCM) Transaction Date: May 20, 2026 | Filing ID: 064778
Read more